Lurbinectedin is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for ...
Analysts at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a research report issued to clients and investors on Monday. The brokerage set a “hold” ...